Policies to promote affordability and access across the life cycle of costly new drugs
Strategic collaboration among countries and sectors on policies that prioritise equity throughout the full medicine life cycle could make innovative therapies more affordable and accessible globally, argue <b>Krista Kruja and colleagues</b>
Authors
- Jorge Mestre-Ferrándiz (ORCID: https://orcid.org/0000-0003-0529-1321)
- Krista Kruja (ORCID: https://orcid.org/0000-0003-3130-8908)
- Michael M. Hopkins (ORCID: https://orcid.org/0000-0002-8401-6573)
- Suerie Moon (ORCID: https://orcid.org/0000-0001-8504-1212)
- Bettina Ryll (ORCID: https://orcid.org/0000-0002-2652-8474)
- Zoltán Kaló (ORCID: https://orcid.org/0000-0001-7762-2607)
Institutions
- Semmelweis University (HU)
- University of Sussex (GB)
- Stockholm School of Economics (SE)
- Engineering Link (Canada) (CA)
- World Health Organization Regional Office for Europe (DK)
- Syreon Research Institute (Hungary) (HU)
- Universidad Carlos III de Madrid (ES)
- Graduate Institute of International and Development Studies (CH)
Publication Details
- Journal
- BMJ
- Published
- 2025-11-11
- DOI
- https://doi.org/10.1136/bmj-2025-086516
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Helse- og Omsorgsdepartementet